Emerald Mutual Fund Advisers Trust Purchases 26,202 Shares of LivaNova PLC $LIVN

Emerald Mutual Fund Advisers Trust lifted its position in shares of LivaNova PLC (NASDAQ:LIVN) by 8.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 349,664 shares of the company’s stock after acquiring an additional 26,202 shares during the period. Emerald Mutual Fund Advisers Trust owned approximately 0.64% of LivaNova worth $18,315,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in LivaNova by 4.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company’s stock valued at $1,394,000 after purchasing an additional 1,360 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of LivaNova by 4.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company’s stock valued at $32,012,000 after purchasing an additional 36,094 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of LivaNova by 10.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company’s stock worth $6,633,000 after buying an additional 15,405 shares in the last quarter. Intech Investment Management LLC lifted its position in shares of LivaNova by 19.6% during the 1st quarter. Intech Investment Management LLC now owns 43,879 shares of the company’s stock worth $1,724,000 after buying an additional 7,195 shares during the last quarter. Finally, Strs Ohio bought a new stake in shares of LivaNova during the 1st quarter worth $130,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on LIVN. Wall Street Zen upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $66.00 price target on shares of LivaNova in a report on Friday, January 9th. Stifel Nicolaus increased their price objective on shares of LivaNova from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. KeyCorp assumed coverage on shares of LivaNova in a research report on Friday, December 19th. They issued an “overweight” rating and a $81.00 target price on the stock. Finally, Barclays upped their price target on shares of LivaNova from $58.00 to $67.00 and gave the stock an “equal weight” rating in a report on Friday, January 9th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, LivaNova has an average rating of “Moderate Buy” and a consensus target price of $69.38.

LivaNova Stock Up 1.0%

NASDAQ:LIVN opened at $63.88 on Friday. LivaNova PLC has a one year low of $32.48 and a one year high of $65.57. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.33 and a quick ratio of 1.12. The company has a market cap of $3.49 billion, a PE ratio of -15.97 and a beta of 0.97. The firm’s 50 day simple moving average is $61.89 and its 200 day simple moving average is $55.06.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.